Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lyophilized Sterile Fecal Filtrate vs FMT for Recurrent CDI
NCT03806803Phase 2Completed
- Sponsor
- University of Alberta
- Start
- Mar 2019
- Primary completion
- Mar 2024
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lyophilized sterile fecal filtrate in Clostridioides difficile infection (CDI) (2 arms), sponsored by University of Alberta. Primary endpoint: Resolution of Recurrent Clostridioides Difficile Infection at 8 weeks. Started Mar 2019; status: completed.
02
Drugs
lyophilized sterile fecal filtrate
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03806803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03806803.